Rapid response to sorafenib in metastatic medullary thyroid carcinoma

Experimental and Clinical Endocrinology and Diabetes

Volumn 119, Issue 3, 2011, Pages 151-155

  Frank Raue, K ^a   Ganten, M ^b   Kreissl, M C ^c   Raue, F ^a  

^a Endocrine Practice   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

medullary thyroid carcinoma; RET proto oncogene; sorafinib; tyrosine kinase inhibitors

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; SORAFENIB; TUMOR MARKER;

ADULT; ARTICLE; ASCITES; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIVER FAILURE; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; THYROID NEOPLASMS;

EID: 79952101581     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1262836     Document Type: Article

References (15)

1. Kloos RT, Eng C, Evans DB, etal. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009 19 565-612
2. Frank-Raue K, Fabel M, Delorme S, etal. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007 157 215-220 (Pubitemid 47233127)
3. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, etal. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007 92 3466-3469 (Pubitemid 47435321)
4. Schlumberger MJ, Elisei R, Bastholt L, etal. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009 27 3794-3801
5. Cohen EE, Rosen LS, Vokes EE, etal. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008 26 4708-4713
6. Wells SA Jr, Gosnell JE, Gagel RF, etal. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010 28 767-772
7. Kurzrock R, Sherman S, Pfister D, etal. Preliminary results of a phase 1 study of XL184, a Met, VEGFR2 and Ret kinase inhibitor (TKI), administered orally to patients with medullary thyroid cancer (MTC). acta medica portuguesa 2009 1
8. Kloos RT, Ringel MD, Knopp MV, etal. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009 27 1675-1684
9. Kober F, Hermann M, Handler A, etal. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J clin Oncol 2007 25 14065
10. Chintala L, Kurzrock R, Fu S, etal. Phase 1 study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156). J Clin Oncol 2008 26 3593
11. Lam ET, Ringel MD, Kloos RT, etal. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28 2323-2330
12. Therasse P, Arbuck SG, Eisenhauer EA, etal. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 205-216
13. Laure Giraudet A, Al Ghulzan A, Auperin A, etal. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008 158 239-246 (Pubitemid 351298542)
14. Akeno-Stuart N, Croyle M, Knauf JA, etal. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 2007 67 6956-6964 (Pubitemid 47105543)
15. Carlomagno F, Anaganti S, Guida T, etal. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006 98 326-334 (Pubitemid 43338212)